Novacyt products included in UK testing framework for Covid-19 variants

Writer,

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Diagnostics group Novacyt said its Covid-19 testing products had been included in a UK framework for identifying variants of the disease.

The company's SARS-CoV-2 polymerase chain reaction genotyping portfolio had been included in the NHS England Framework for detecting variants of concern.

Novacyt also announced the launch of two new PCR assays to detect SARS-CoV-2 variants of concern.

At 8:06am: (LON:NCYT) Novacyt S.A. share price was 0p at 897p